Celgene Gives Reassurances That Key Products And Programs Remain On Track
Celgene's quarterly earnings call was all about reassuring investors that its products and pipeline will deliver the full value of the company's acquisition by Bristol-Myers after the deal closes in the third quarter.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker include a Neulasta biosimilar approval for Sandoz, novel approvals for Celgene's Reblozyl and Giskit B.V.'s ExEm Foam, and a submission for Regeneron's Ebola candidate.
The latest drug development news and highlights from our US FDA Performance Tracker.
MacroGenics, Amgen, Celgene, Forty Seven and Iovance are all set to enjoy a good ASCO meeting with promising data for key products revealed in the abstract drop.